[go: up one dir, main page]

SE0402221D0 - Treatment of insufficient perfusion - Google Patents

Treatment of insufficient perfusion

Info

Publication number
SE0402221D0
SE0402221D0 SE0402221A SE0402221A SE0402221D0 SE 0402221 D0 SE0402221 D0 SE 0402221D0 SE 0402221 A SE0402221 A SE 0402221A SE 0402221 A SE0402221 A SE 0402221A SE 0402221 D0 SE0402221 D0 SE 0402221D0
Authority
SE
Sweden
Prior art keywords
treatment
insufficient perfusion
composition
perfusion
insufficient
Prior art date
Application number
SE0402221A
Other languages
English (en)
Original Assignee
Aerocrine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerocrine Ab filed Critical Aerocrine Ab
Priority to SE0402221A priority Critical patent/SE0402221D0/sv
Publication of SE0402221D0 publication Critical patent/SE0402221D0/sv
Priority to US10/573,335 priority patent/US8552068B2/en
Priority to PCT/SE2005/001336 priority patent/WO2006031191A1/en
Priority to EP05783432A priority patent/EP1789060A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0402221A 2004-09-14 2004-09-14 Treatment of insufficient perfusion SE0402221D0 (sv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE0402221A SE0402221D0 (sv) 2004-09-14 2004-09-14 Treatment of insufficient perfusion
US10/573,335 US8552068B2 (en) 2004-09-14 2005-09-14 Compositions and methods
PCT/SE2005/001336 WO2006031191A1 (en) 2004-09-14 2005-09-14 Compositions comprising compounds capable of forming a reversible bond or association with gaseous nitric oxide
EP05783432A EP1789060A1 (en) 2004-09-14 2005-09-14 Compositions comprising compounds capable of forming a reversible bond or association with gaseous nitric oxide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0402221A SE0402221D0 (sv) 2004-09-14 2004-09-14 Treatment of insufficient perfusion

Publications (1)

Publication Number Publication Date
SE0402221D0 true SE0402221D0 (sv) 2004-09-14

Family

ID=33157545

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0402221A SE0402221D0 (sv) 2004-09-14 2004-09-14 Treatment of insufficient perfusion

Country Status (4)

Country Link
US (1) US8552068B2 (sv)
EP (1) EP1789060A1 (sv)
SE (1) SE0402221D0 (sv)
WO (1) WO2006031191A1 (sv)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0613856D0 (en) * 2006-07-13 2006-08-23 Isis Innovation Method for reducing spasms
US20080146579A1 (en) * 2006-12-15 2008-06-19 N.V. Nutricia Treatment of patients with chronic pulmonary diseases and nutritional compositions therefore
US8043246B2 (en) 2007-09-21 2011-10-25 Enox Biopharma, Inc. Antimicrobial gas-releasing ear drainage tubes
EP2707103A2 (en) * 2011-05-09 2014-03-19 Topical Therapeutic Agent (TTA) Ltd. Nitric oxide-sequestering topical formulations
US10681914B2 (en) 2012-05-29 2020-06-16 Neozyme International, Inc. Non-toxic plant agent compositions and methods and uses thereof
EP3760592B8 (en) 2012-05-29 2025-02-26 Neozyme International, Inc. Use of a bio-catalytic composition in treating a contaminated water
US10557234B2 (en) 2012-05-29 2020-02-11 Neozyme International, Inc. Papermaking additive compositions and methods and uses thereof
US10334856B2 (en) 2012-05-29 2019-07-02 Neozyme International, Inc. Non-toxic pest control compositions and methods and uses thereof
US11193077B1 (en) 2013-03-13 2021-12-07 Airworthy Autogas, Llc Gasoline for aircraft use
GB2579240B (en) 2018-11-27 2020-12-16 Attgeno Ab New processes, compositions and medical uses
US12010992B2 (en) 2020-04-26 2024-06-18 Neozyme International, Inc. Dry powdered compositions and methods and uses thereof
AU2021265767A1 (en) 2020-04-26 2022-12-01 Neozyme International, Inc. Non-toxic fire extinguishing compositions, devices and methods of using same
GB202007929D0 (en) 2020-05-27 2020-07-08 Attgeno Ab New medical uses
GB202306258D0 (en) 2023-04-27 2023-06-14 Attgeno Ab New medical uses

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE468416B (sv) 1991-09-27 1993-01-18 Lars Erik Gustafsson Saett att faststaella aktuell lungfunktion samt anordning foer att indikera naemnda lungfunktion
EP1023905B1 (en) 1991-11-14 2005-01-26 The Brigham And Women's Hospital, Inc. Pharmaceutical composition containing S-nitroso-immunoglobulins and use thereof
US5646181A (en) * 1992-07-02 1997-07-08 Research Foundation Of State University Of New York Method and compositions for treating impotence
AU6232794A (en) 1993-01-29 1994-08-15 Brigham And Women's Hospital The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury
EP0804244A1 (en) 1993-03-26 1997-11-05 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
ATE191560T1 (de) 1993-07-06 2000-04-15 Aerocrine Ab System zur feststellung von no-pegeln in ausgeatmeter luft und diagnostische verfahren für zu abnormalen no-pegeln in beziehung stehenden abweichungen
US6255277B1 (en) * 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
US6087479A (en) * 1993-09-17 2000-07-11 Nitromed, Inc. Localized use of nitric oxide-adducts to prevent internal tissue damage
DE69617719D1 (de) 1995-10-20 2002-01-17 Air Liquide Pharmazeutische zusammensetzung von stickstoffmonoxid
US6294517B1 (en) * 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US20020061879A1 (en) 1996-02-02 2002-05-23 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
DE19654895C2 (de) 1996-02-07 2000-07-27 Sanol Arznei Schwarz Gmbh Detektionsverfahren
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US6589759B1 (en) 1999-03-30 2003-07-08 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
US6737447B1 (en) * 1999-10-08 2004-05-18 The University Of Akron Nitric oxide-modified linear poly(ethylenimine) fibers and uses thereof
EP1284653B1 (en) 2000-05-09 2007-11-28 Nitromed, Inc. Infrared thermography and treatment of sexual dysfunctions
AU2001264729A1 (en) * 2000-05-22 2001-12-03 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
US6706274B2 (en) * 2001-01-18 2004-03-16 Scimed Life Systems, Inc. Differential delivery of nitric oxide
US6673338B1 (en) * 2001-09-10 2004-01-06 The United States Of America As Represented By The Department Of Health And Human Services Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same
WO2004026345A1 (en) 2002-09-19 2004-04-01 New York University Control of nitric oxide bioactivity by perfluorocarbons

Also Published As

Publication number Publication date
US8552068B2 (en) 2013-10-08
WO2006031191A8 (en) 2006-12-28
EP1789060A1 (en) 2007-05-30
US20080293813A1 (en) 2008-11-27
WO2006031191A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
SE0402221D0 (sv) Treatment of insufficient perfusion
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
WO2013061083A3 (en) Therapeutic agents and uses thereof
DK1853250T3 (da) Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
UY27720A1 (es) Aroilpiridinonas monocíclicas,
NO20080068L (no) Topisk unguale formuleringer
MX2010010954A (es) Farmaco contra cancer de higado.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
AR063604A1 (es) Atenuacion de la vasoconstriccion inducida por un portador de oxigeno vasoactivo
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
EP1962771A4 (en) DENTAL COMPOSITIONS WITH RADIANT-IN-HEAT TRANSFORMERS AND THEIR USE
WO2008048514A3 (en) Topical nitric oxide as a treatment of autoimmune diseases
TW200626558A (en) Indazolone derivatives
PL2167117T3 (pl) Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
EP1962843A4 (en) USE OF PARP-1 INHIBITORS
SE0300971D0 (sv) Nitric oxide in treatment of inflammation
ATE540690T1 (de) Insulinkombinationen
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
TWD133685S1 (zh) 垂飾
WO2009099998A3 (en) Therapeutic treatment for lung conditions
SG196863A1 (en) Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage